RxDoctor Payments Data

Sanjay Dhar, MD

Cardiovascular Disease · Santa Rosa, CANPI 1811074586

Payments from drug & device makers

$21,286in general payments, 2019–2025

Across 720 payments — averaging $29.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$4K
  • Abbott$3K
  • AstraZeneca$1K
  • Amgen$1K
  • Edwards Lifesciences$1K
  • Merck$1K
  • plus $10K from 39 others

What the payments were for

  • Travel & lodging$1,4607%
  • Food & beverage$19,61792%
  • Education$2101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$21,286 in reported general payments places this provider in the 80th percentile of 2,184 cardiovascular disease providers in California.

See all cardiovascular disease providers in California

Medicare billing

Part B allowed, 2024
$953,775
Medicare patients
2,850
Services billed
10,755

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis97$2,612,572
EliquisApixaban1,079$1,298,863
EntrestoSacubitril/Valsartan436$513,537
XareltoRivaroxaban362$409,486
VyndaqelTafamidis Meglumine12$268,066
Repatha SureclickEvolocumab190$164,757
JardianceEmpagliflozin129$136,733
CamzyosMavacamten12$101,605
FarxigaDapagliflozin Propanediol98$79,348
MultaqDronedarone Hcl63$72,175
Repatha SyringeEvolocumab71$48,282
WegovySemaglutide35$46,611
NexletolBempedoic Acid48$33,207
Ezetimibe724$25,690
BrilintaTicagrelor39$22,734

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis, Vyndaqel$428$4,179,5011,188 claims
NovartisEntresto$629$513,537436 claims
Johnson & JohnsonXarelto$668$409,486362 claims
Boehringer IngelheimJardiance, Pradaxa$773$140,900142 claims
AstraZenecaFarxiga, Brilinta$1,192$102,082137 claims
E.r. Squibb & Sons, L.L.C.Camzyos$713$101,60512 claims
Sanofi-aventis U.S. LLCMultaq$294$72,17563 claims
Novo NordiskWegovy$14$46,61135 claims
Esperion Therapeutics, Inc.Nexletol$632$33,20748 claims
MerckVerquvo$1,072$15,12415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,184 cardiovascular disease providers in California.

Other cardiovascular disease in Santa Rosa

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →